EU approval and labelling information
Colorectal cancer (CRC)
Avastin in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of patients with metastatic carcinoma of the colon or rectum.
Breast cancer
Avastin in combination with paclitaxel or docetaxel is indicated for first-line treatment of patients with metastatic breast cancer.
Non-small cell lung cancer (NSCLC)
Avastin, in addition to platinum-based chemotherapy, is indicated for first-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.
Renal cell cancer (RCC)
Avastin in combination with interferon alfa-2a is indicated for first line treatment of patients with advanced and/or metastatic renal cell cancer.
The European Summary of Product Characteristics provides comprehensive clinical, pharmacological and prescribing information about Avastin.
European SPC (English version)
European SPC (other languages)
For SPCs in non-European countries, please refer to your local health authorities
- Disclaimer: Avastin.net is a comprehensive resource for healthcare professionals outside the US. If you are a US resident please visit www.avastin.comThe information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.